Overview

Efficacy of Lu 31-130 in Patients With Schizophrenia

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
0
Participant gender:
All
Summary
The main purpose with the study is to explore the efficacy and safety of Lu 31-130 in patients suffering from schizophrenia compared to a standard antipsychotic drug.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
H. Lundbeck A/S
Treatments:
Olanzapine
Criteria
Inclusion Criteria:

- The subject has a primary diagnosis of schizophrenia

- The subject experiences clinically significant symptoms

- The subject is willing to be hospitalized during the initial period of the study

- The subject has normal serum values of parameters associated with liver function